XML 16 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common stock
Retained earnings
Retained earnings
Cumulative Effect, Period of Adoption, Adjustment
Accumulated other comprehensive income (loss)
Accumulated other comprehensive income (loss)
Cumulative Effect, Period of Adoption, Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Cumulative effect of adoption of new accounting standards $ 679,723 $ (3,740) $ 300,729 $ 374,673 $ (3,740) $ 4,321 $ 0
Common stock shares outstanding, beginning balance (in shares) at Dec. 31, 2019     23,890,855        
Beginning balance at Dec. 31, 2019 679,723 $ (3,740) $ 300,729 374,673 $ (3,740) 4,321 $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 52,392     52,392      
Share-based compensation expense 2,030   $ 2,030        
Common stock issued - Option exercise; stock grants (in shares)     (127,273)        
Common stock issued - Option exercise; stock grants 782   $ 782        
Other comprehensive income 28,456         28,456  
Dividends declared on common stock (10,556)     (10,556)      
Common stock repurchased (in shares)     (2,023,924)        
Common stock repurchased (52,781)   $ (23,119) (29,662)      
Common stock shares outstanding, ending balance (in shares) at Sep. 30, 2020     21,994,204        
Ending balance at Sep. 30, 2020 696,306   $ 280,422 383,107   32,777  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Cumulative effect of adoption of new accounting standards 694,649   $ 290,871 375,268   28,510  
Common stock shares outstanding, beginning balance (in shares) at Jun. 30, 2020     23,007,400        
Beginning balance at Jun. 30, 2020 694,649   $ 290,871 375,268   28,510  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 26,349     26,349      
Share-based compensation expense 846   $ 846        
Common stock issued - Option exercise; stock grants (in shares)     (5,576)        
Common stock issued - Option exercise; stock grants 0   $ 0        
Other comprehensive income 4,267         4,267  
Dividends declared on common stock (3,450)     (3,450)      
Common stock repurchased (in shares)     (1,018,772)        
Common stock repurchased (26,355)   $ (11,295) (15,060)      
Common stock shares outstanding, ending balance (in shares) at Sep. 30, 2020     21,994,204        
Ending balance at Sep. 30, 2020 696,306   $ 280,422 383,107   32,777  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Cumulative effect of adoption of new accounting standards 696,306   280,422 383,107   32,777  
Cumulative effect of adoption of new accounting standards $ 717,750   $ 278,505 403,888   35,357  
Common stock shares outstanding, beginning balance (in shares) at Dec. 31, 2020 21,796,904   21,796,904        
Beginning balance at Dec. 31, 2020 $ 717,750   $ 278,505 403,888   35,357  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 85,990     85,990      
Share-based compensation expense (in shares)     0        
Share-based compensation expense 2,557   $ 2,557        
Common stock issued - Option exercise; stock grants (in shares)     (245,630)        
Common stock issued - Option exercise; stock grants 2,383   $ 2,383        
Other comprehensive income (13,264)         (13,264)  
Dividends declared on common stock (16,171)     (16,171)      
Common stock repurchased (in shares)     (1,595,886)        
Common stock repurchased $ (68,869)   $ (27,364) (41,505)      
Common stock shares outstanding, ending balance (in shares) at Sep. 30, 2021 20,446,648   20,446,648        
Ending balance at Sep. 30, 2021 $ 710,376   $ 256,081 432,202   22,093  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Cumulative effect of adoption of new accounting standards 708,731   $ 260,774 420,111   27,846  
Common stock shares outstanding, beginning balance (in shares) at Jun. 30, 2021     20,791,659        
Beginning balance at Jun. 30, 2021 708,731   $ 260,774 420,111   27,846  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 27,170     27,170      
Share-based compensation expense (in shares)     0        
Share-based compensation expense 892   $ 892        
Common stock issued - Option exercise; stock grants (in shares)     52,265        
Common stock issued - Option exercise; stock grants 339   $ 339        
Other comprehensive income (5,753)         (5,753)  
Dividends declared on common stock (5,259)     (5,259)      
Common stock repurchased (in shares)     397,276        
Common stock repurchased $ (15,744)   $ (5,924) (9,820)      
Common stock shares outstanding, ending balance (in shares) at Sep. 30, 2021 20,446,648   20,446,648        
Ending balance at Sep. 30, 2021 $ 710,376   $ 256,081 432,202   22,093  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Cumulative effect of adoption of new accounting standards $ 710,376   $ 256,081 $ 432,202   $ 22,093